Luisenkrankenhaus Düsseldorf

Hospital


Location: Düsseldorf, Germany (DE) DE

ISNI: -

ROR: https://ror.org/01dc7nx94

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial (2016) Schroeder L, Rack B, Sommer H, Koch JG, Weissenbacher T, Janni W, Schneeweiss A, et al. Journal article Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+ (2014) Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Journal article Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study (2014) Fasching P, Fehm T, Kellner S, De Waal J, Rezal M, Baler B, Baake G, et al. Journal article Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (2014) Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Journal article Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer (2014) Jaeger BAS, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, et al. Journal article PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer (2014) Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, et al. Journal article Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44) (2014) Gerber B, Von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, et al. Journal article Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro) (2014) Von Minckwitz G, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, et al. Journal article
‹ 1 2 3 ›